Arterra Bioscience Valuation

Q: What is the Fair Price of ARBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ARBS (€2) is trading above our estimate of [[fair value]] (€1.41)

Is ARBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ARBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ARBS (€2) is trading above our estimate of fair value (€1.41)

Significantly Below Fair Value: ARBS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ARBS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ARBS. This is calculated by dividing ARBS's market cap by their current preferred multiple.
What is ARBS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	€13.32m

ARBS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	6.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does ARBS's PE Ratio compare to its peers?

The above table shows the PE ratio for ARBS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.3x
SHE Shedir Pharma Group	7.7x	n/a	€43.4m
A318160 Cell Bio Human TechLtd	31.8x	n/a	₩28.3b
GEN Genomed Spólka Akcyjna	64.6x	n/a	zł38.3m
BST Biotechnology Assets	12.9x	n/a	€20.3m
ARBS Arterra Bioscience	12.4x	n/a	€13.3m

Price-To-Earnings vs Peers: ARBS is good value based on its Price-To-Earnings Ratio (12.4x) compared to the peer average (29.3x).

Price to Earnings Ratio vs Industry

How does ARBS's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: ARBS is good value based on its Price-To-Earnings Ratio (12.4x) compared to the European Biotechs industry average (29.2x).

Price to Earnings Ratio vs Fair Ratio

What is ARBS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ARBS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	12.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ARBS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.